FDA Plans Further Audits Of Telavancin Study Sites; No Major Problems To Date

Firm says FDA and company audits of telavancin clinical trial data are progressing well; no predictions on how long process may take.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet